查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1584115

Alpha-1抗胰蛋白酶缺乏症治療市場，按治療類型、給藥途徑、最終用戶、國家和地區 - 2024-2032年產業分析、市場規模、市場佔有率和預測

Alpha-1 Antitrypsin Deficiency Disease Treatment Market, By Treatment Type, By Route of Administration, By End-User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 288 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

報告要點

2023年Alpha-1抗胰蛋白酶缺乏症治療市場規模為26.3043億美元，2024年至2032年年複合成長率為10.10%。

Alpha-1抗胰蛋白酶缺乏症治療市場-市場動態

人們對遺傳性疾病的認知不斷提高，推動了 Alpha-1 抗胰蛋白酶缺乏症治療市場的成長

人們對遺傳性疾病的認知不斷提高，推動了 Alpha-1 抗胰蛋白酶（AAT）缺乏症治療市場的成長，並且越來越重視早期診斷和有效管理。 AAT 缺乏症是一種影響肺部和肝臟健康的遺傳性疾病，促使許多衛生組織和政府擴大篩檢計畫並向公眾宣傳其風險。例如，世界衛生組織（WHO）強調了基因檢測在檢測遺傳性疾病的重要性。製藥公司也加速研發力度，以創造創新療法。這種意識的激增導致全球 AAT 缺乏症患者對針對性治療的需求更大，並改善了醫療保健的可近性。

Alpha-1 抗胰蛋白酶缺乏症治療市場 - 關鍵見解

根據研究分析師分享的分析，預計全球市場在預測期內（2024-2032）每年將以 10.10%左右的年複合成長率成長

根據治療類型細分，預計增強療法將在2023年顯示最大的市場佔有率

依給藥途徑細分，2023年靜脈注射為主導類型

依地區分類，北美是2023年的主要收入來源

Alpha-1 抗胰蛋白酶缺乏症治療市場-細分分析：

全球 Alpha-1 抗胰蛋白酶缺乏症治療市場根據治療類型、給藥途徑、最終用戶和地區進行細分。

根據治療類型，市場分為四類：增強療法、支氣管擴張劑療法、氧氣療法和類固醇療法。強化療法因其在補充 AAT 水平方面的直接作用而具有最高優先級。支氣管擴張劑療法用於症狀管理，而氧氣療法和類固醇療法用於嚴重病例。

根據給藥途徑，市場分為三類：靜脈注射、口服和吸入。靜脈途徑因其在提供增強治療方面的有效性而具有最高優先順序。口服給藥是為了方便使用，吸入給藥在特定情況下用於緩解症狀。

Alpha-1 抗胰蛋白酶缺乏症治療市場 - 地理洞察

Alpha-1 抗胰蛋白酶（AAT）缺乏症治療市場表現出顯著的地域差異，其中北美由於其先進的醫療基礎設施和對遺傳性疾病認知的高度重視而引領市場。尤其是美國，在 Alpha-1 基金會等組織的支持下，採取了增加基因檢測和新生兒篩檢計畫等措施。歐洲緊隨其後，德國和英國等國家大力投資研發以解決 AAT 缺陷。例如，歐洲呼吸學會一直在積極推動宣傳活動，以改善早期檢測和治療方案。在亞太地區，醫療保健支出的增加和對遺傳性疾病的認知不斷提高推動市場成長。日本和中國日益擴大其醫療保健系統，包括對 AAT 缺乏症等遺傳性疾病進行更全面的篩檢。拉丁美洲、中東和非洲逐漸受到關注，目的是改善醫療保健和診斷服務的機會的舉措，儘管這些地區仍然面臨意識和基礎設施方面的挑戰。

Alpha-1抗胰蛋白酶缺乏症治療市場-競爭格局：

Grifols 和Takeda Pharmaceuticals等公司是該地區的知名企業。2023年，Grifols 擴建了位於北卡羅來納州的Prolastin-C Liquid（AAT 增強療法）製造工廠，以滿足不斷成長的需求。同時，Takeda積極參與目的是增強 AAT 治療解決方案的研究合作。2024年，市場主要參與者 CSL Behring 宣布與歐洲肺臟基金會建立合作關係，以提高人們對 AAT 缺乏症的認知。此次合作目的是支持早期診斷和治療，特別是在疾病識別率較低的地區。亞太地區雖然在成長，但仍處於早期階段，當地醫療機構和全球公司之間形成了重要的合作夥伴關係，以改善 AAT 療法的可及性。這些發展凸顯了策略性舉措對於推動全球 AAT 治療市場競爭優勢的重要性。

最新進展：

2024年 1月，Sanofi宣布收購 Inhibrx, Inc.，其中包括治療 Alpha-1 抗胰蛋白酶缺乏症（AATD）的候選藥物 INBRX-101。此次收購是Sanofi增強其罕見疾病和免疫學產品組合策略的一部分。

2023年 4月，Arrowhead Pharmaceuticals 宣佈在一項針對 Alpha-1 抗胰蛋白酶缺乏性肝病（AATD-LD）的3 期臨床研究中，首例患者使用其研究療法 Fazirsiran 進行治療。這一里程碑觸發Takeda向 Arrowhead 支付 4000萬美元。

目錄

第1章 Alpha-1 抗胰蛋白酶缺乏症治療市場概述

  • 研究範圍
  • 市場預估年份

第2章 執行摘要

  • 市場摘錄
    • Alpha-1 抗胰蛋白酶缺乏症治療市場摘錄（依治療類型）
    • Alpha-1 抗胰蛋白酶缺乏症治療市場摘錄（依給藥途徑）
    • Alpha-1 抗胰蛋白酶缺乏症治療市場摘錄（依最終使用者）
    • Alpha-1 抗胰蛋白酶缺乏症治療市場摘錄（依國家）
    • Alpha-1 抗胰蛋白酶缺乏症治療市場摘錄（依地區）
  • 競爭洞察

第3章 Alpha-1 抗胰蛋白酶缺乏症治療主要市場趨勢

  • Alpha-1 抗胰蛋白酶缺乏症治療市場促進因素
    • 市場促進因素的影響分析
  • Alpha-1抗胰蛋白酶缺乏症治療市場限制
    • 市場限制影響分析
  • Alpha-1 抗胰蛋白酶缺乏症治療市場機會
  • Alpha-1抗胰蛋白酶缺乏症治療市場未來趨勢

第4章 Alpha-1 抗胰蛋白酶缺乏症治療產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景圖
  • 規範架構分析

第5章 Alpha-1 抗胰蛋白酶缺乏症治療市場：COVID-19 影響分析

  • COVID-19 之前的影響分析
  • COVID-19 後影響分析
    • 表現最佳的市場區隔
    • 邊際成長市場區隔
    • 最寬鬆的市場區隔
    • 邊際損失市場區隔

第6章 Alpha-1 抗胰蛋白酶缺乏症治療市場模式

  • Alpha-1 抗胰蛋白酶缺乏症治療市場佔有率分析，2023年
  • 依主要製造商分類的細分資料
    • 既有參與者分析
    • 新興參與者分析

第7章 Alpha-1 抗胰蛋白酶缺乏症治療市場 - 依治療類型

  • 概述
    • 依治療類型分類的細分市場佔有率分析
    • 增強療法
    • 支氣管擴張劑治療
    • 氧氣治療
    • 類固醇治療

第8章 Alpha-1 抗胰蛋白酶缺乏症治療市場 - 依給藥途徑

  • 概述
    • 依給藥途徑分類的細分市場佔有率分析
    • 靜脈
    • 口服
    • 吸入

第9章 Alpha-1 抗胰蛋白酶缺乏症治療市場 - 依最終用戶

  • 概述
    • 依最終用戶分類的細分市場佔有率分析
    • 醫院
    • 專科診所
    • 家庭護理設置

第10章 Alpha-1 抗胰蛋白酶缺乏症治療市場 - 依地理位置

  • 介紹
    • 依地理位置分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • Alpha-1 抗胰蛋白酶缺乏症治療北美主要製造商
    • 北美市場規模和預測（依國家）
    • 北美市場規模和預測（依治療類型）
    • 北美市場規模與預測（依管理途徑）
    • 北美市場規模和預測（依最終用戶）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • Alpha-1 抗胰蛋白酶缺乏症治療歐洲主要製造商
    • 歐洲市場規模和預測（依國家）
    • 歐洲市場規模和預測（依治療類型）
    • 歐洲市場規模與預測（依管理途徑）
    • 歐洲市場規模和預測（依最終用戶）
    • 德國
    • 義大利
    • 英國
    • 法國
    • 俄羅斯
    • 荷蘭
    • 瑞典
    • 波蘭
    • 歐洲其他地區
  • 亞太地區（APAC）
    • 概述
    • Alpha-1抗胰蛋白酶缺乏症治療藥物亞太地區主要製造商
    • 亞太地區市場規模與預測（依國家）
    • 亞太地區市場規模與預測（依治療類型）
    • 亞太地區市場規模與預測（依管理途徑）
    • 亞太地區市場規模和預測（依最終用戶）
    • 印度
    • 中國
    • 日本
    • 韓國
    • 澳洲
    • 泰國
    • 印尼
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲
    • 概述
    • Alpha-1 抗胰蛋白酶缺乏症治療藥物拉丁美洲主要製造商
    • 拉丁美洲市場規模與預測（依國家）
    • 拉丁美洲市場規模與預測（依治療類型）
    • 拉丁美洲市場規模與預測（依管理途徑）
    • 拉丁美洲市場規模和預測（依最終用戶）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲
    • 概述
    • Alpha-1 抗胰蛋白酶缺乏症治療藥物中東和非洲主要製造商
    • 中東和非洲市場規模及預測（依國家）
    • 中東和非洲市場規模及預測（依治療類型）
    • 中東和非洲市場規模及預測（依管理途徑）
    • 中東和非洲市場規模和預測（依最終用戶）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • MEA其他地區

第11章 主要供應商分析 - Alpha-1 抗胰蛋白酶缺乏症治療產業

  • 競爭儀表板
  • 公司簡介
    • Adverum Biotechnologies, Inc.
    • Arrowhead Pharmaceuticals, Inc.
    • AstraZeneca PLC
    • Baxter International Inc.
    • Biogen Inc.
    • CSL Behring LLC
    • GlaxoSmithKline plc
    • Grifols SA
    • Kamada Ltd.
    • LFB Biopharmaceuticals
    • Pfizer Inc.
    • Prometic Life Sciences Inc.
    • Shire plc
    • Takeda Pharmaceutical Company Limited
    • Vertex Pharmaceuticals Incorporated
    • Others

第12章 360 度分析師視角

第13章 附錄

  • 研究方法
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
簡介目錄
Product Code: ANV4098

REPORT HIGHLIGHT

Alpha-1 Antitrypsin Deficiency Disease Treatment Market size was valued at USD 2,630.43 Million in 2023, expanding at a CAGR of 10.10% from 2024 to 2032.

The Alpha-1 Antitrypsin Deficiency (AATD) Disease Treatment Market is focused on addressing the needs of individuals with AATD, a genetic disorder that leads to the accumulation of abnormal alpha-1 antitrypsin protein in the liver, resulting in lung and liver disease. Treatments primarily include augmentation therapy, aimed at replacing the deficient protein, as well as liver and lung transplants in severe cases. Increasing awareness about genetic disorders and advancements in gene therapy are boosting research efforts in the market. Despite growing demand, limited treatment availability and high costs remain major restraints. Ongoing research into innovative therapies, such as CRISPR-based solutions, presents opportunities for expanding treatment options. According to the World Health Organization, about 1 in 2,500 individuals globally are affected by AATD, further emphasizing the need for improved and accessible treatments.

Alpha-1 Antitrypsin Deficiency Disease Treatment Market- Market Dynamics

Rising Awareness of Genetic Disorders Fuels Growth in the Alpha-1 Antitrypsin Deficiency Disease Treatment Market

The rising awareness of genetic disorders is driving growth in the Alpha-1 Antitrypsin (AAT) Deficiency Disease Treatment Market, with increasing emphasis on early diagnosis and effective management. AAT deficiency, a genetic condition affecting lung and liver health, has prompted numerous health organizations and governments to expand screening programs and educate the public about its risks. For instance, the World Health Organization (WHO) has highlighted the importance of genetic testing in detecting hereditary conditions. Pharmaceutical companies are also accelerating research and development efforts to create innovative therapies. This surge in awareness is leading to greater demand for targeted treatments and improved healthcare access for AAT deficiency patients worldwide.

Alpha-1 Antitrypsin Deficiency Disease Treatment Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 10.10% over the forecast period (2024-2032)

Based on Treatment Type segmentation, Augmentation Therapy was predicted to show maximum market share in the year 2023

Based on Route of Administration segmentation, Intravenous was the leading type in 2023

On the basis of region, North America was the leading revenue generator in 2023

Alpha-1 Antitrypsin Deficiency Disease Treatment Market- Segmentation Analysis:

The Global Alpha-1 Antitrypsin Deficiency Disease Treatment Market is segmented on the basis of Treatment Type, Route of Administration, End-User, and Region.

The market is divided into four categories based on Treatment Type: Augmentation Therapy, Bronchodilator Therapy, Oxygen Therapy, and Steroid Therapy. Augmentation Therapy holds the highest priority due to its direct role in replenishing AAT levels. Bronchodilator Therapy is used for symptom management, while Oxygen Therapy and Steroid Therapy are used for severe cases.

The market is divided into three categories based on the Route of Administration: Intravenous, Oral, and Inhalation. The Intravenous route holds the highest priority due to its effectiveness in delivering augmentation therapy. Oral administration follows for ease of use, with Inhalation being utilized for symptom relief in specific cases.

Alpha-1 Antitrypsin Deficiency Disease Treatment Market- Geographical Insights

The Alpha-1 Antitrypsin (AAT) Deficiency Disease Treatment Market shows significant geographical variation, with North America leading the market due to its advanced healthcare infrastructure and strong emphasis on genetic disorder awareness. The U.S., in particular, has seen initiatives such as increased genetic testing and newborn screening programs, supported by organizations like the Alpha-1 Foundation. Europe follows closely, with countries like Germany and the UK investing heavily in research and development to address AAT deficiency. For instance, the European Respiratory Society has been actively promoting awareness campaigns to improve early detection and treatment options. In the Asia-Pacific region, increasing healthcare expenditure and growing awareness about genetic disorders are driving market growth. Japan and China are expanding their healthcare systems to include more comprehensive screening for hereditary diseases like AAT deficiency. Latin America and the Middle East & Africa are gradually gaining traction, with initiatives aimed at improving access to healthcare and diagnostic services, although these regions still face challenges in terms of awareness and infrastructure.

Alpha-1 Antitrypsin Deficiency Disease Treatment Market- Competitive Landscape:

Companies like Grifols and Takeda Pharmaceuticals are prominent players in this region. In 2023, Grifols expanded its Prolastin-C Liquid (AAT augmentation therapy) manufacturing facility in North Carolina to meet growing demand. Meanwhile, Takeda is actively involved in research collaborations aimed at enhancing AAT therapy solutions. In 2024, CSL Behring, a key player in the market, announced a partnership with the European Lung Foundation to raise awareness about AAT deficiency. This collaboration aims to support earlier diagnosis and treatment, particularly in regions with lower disorder recognition. Asia-Pacific, though growing, remains in its early stages, with key partnerships forming between local healthcare institutions and global firms to improve access to AAT therapies. These developments underline the importance of strategic initiatives in driving competitive advantage in the AAT treatment market globally.

Recent Developments:

In January 2024, Sanofi announced its acquisition of Inhibrx, Inc., which includes the promising treatment candidate INBRX-101 for Alpha-1 Antitrypsin Deficiency (AATD). This acquisition is part of Sanofi's strategy to enhance its rare diseases and immunology portfolio.

In April 2023, Arrowhead Pharmaceuticals announced the first patient's treatment in a Phase 3 clinical study for Alpha-1 Antitrypsin Deficiency Liver Disease (AATD-LD) using their investigational therapy, Fazirsiran. This milestone triggers a $40 million payment from Takeda to Arrowhead.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL ALPHA-1 ANTITRYPSIN DEFICIENCY DISEASE TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Adverum Biotechnologies, Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Baxter International Inc.
  • Biogen Inc.
  • CSL Behring LLC
  • GlaxoSmithKline plc
  • Grifols S.A.
  • Kamada Ltd.
  • LFB Biopharmaceuticals
  • Pfizer Inc.
  • Prometic Life Sciences Inc.
  • Shire plc
  • Takeda Pharmaceutical Company Limited
  • Vertex Pharmaceuticals Incorporated
  • Others

GLOBAL ALPHA-1 ANTITRYPSIN DEFICIENCY DISEASE TREATMENT MARKET, BY TREATMENT TYPE- MARKET ANALYSIS, 2019 - 2032

  • Augmentation Therapy
  • Bronchodilator Therapy
  • Oxygen Therapy
  • Steroid Therapy

GLOBAL ALPHA-1 ANTITRYPSIN DEFICIENCY DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Intravenous
  • Oral
  • Inhalation

GLOBAL ALPHA-1 ANTITRYPSIN DEFICIENCY DISEASE TREATMENT MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Specialty Clinics
  • Homecare Settings

GLOBAL ALPHA-1 ANTITRYPSIN DEFICIENCY DISEASE TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Alpha-1 Antitrypsin Deficiency Disease Treatment Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Alpha-1 Antitrypsin Deficiency Disease Treatment Market Snippet by Treatment Type
    • 2.1.2. Alpha-1 Antitrypsin Deficiency Disease Treatment Market Snippet by Route of Administration
    • 2.1.3. Alpha-1 Antitrypsin Deficiency Disease Treatment Market Snippet by End-User
    • 2.1.4. Alpha-1 Antitrypsin Deficiency Disease Treatment Market Snippet by Country
    • 2.1.5. Alpha-1 Antitrypsin Deficiency Disease Treatment Market Snippet by Region
  • 2.2. Competitive Insights

3. Alpha-1 Antitrypsin Deficiency Disease Treatment Key Market Trends

  • 3.1. Alpha-1 Antitrypsin Deficiency Disease Treatment Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Alpha-1 Antitrypsin Deficiency Disease Treatment Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Alpha-1 Antitrypsin Deficiency Disease Treatment Market Opportunities
  • 3.4. Alpha-1 Antitrypsin Deficiency Disease Treatment Market Future Trends

4. Alpha-1 Antitrypsin Deficiency Disease Treatment Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Alpha-1 Antitrypsin Deficiency Disease Treatment Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Alpha-1 Antitrypsin Deficiency Disease Treatment Market Landscape

  • 6.1. Alpha-1 Antitrypsin Deficiency Disease Treatment Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Alpha-1 Antitrypsin Deficiency Disease Treatment Market - By Treatment Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Treatment Type, 2023 & 2032 (%)
    • 7.1.2. Augmentation Therapy
    • 7.1.3. Bronchodilator Therapy
    • 7.1.4. Oxygen Therapy
    • 7.1.5. Steroid Therapy

8. Alpha-1 Antitrypsin Deficiency Disease Treatment Market - By Route of Administration

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
    • 8.1.2. Intravenous
    • 8.1.3. Oral
    • 8.1.4. Inhalation

9. Alpha-1 Antitrypsin Deficiency Disease Treatment Market - By End-User

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By End-User, 2023 & 2032 (%)
    • 9.1.2. Hospitals
    • 9.1.3. Specialty Clinics
    • 9.1.4. Homecare Settings

10. Alpha-1 Antitrypsin Deficiency Disease Treatment Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Alpha-1 Antitrypsin Deficiency Disease Treatment Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Alpha-1 Antitrypsin Deficiency Disease Treatment Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Alpha-1 Antitrypsin Deficiency Disease Treatment Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Alpha-1 Antitrypsin Deficiency Disease Treatment Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Alpha-1 Antitrypsin Deficiency Disease Treatment Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Alpha-1 Antitrypsin Deficiency Disease Treatment Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. Adverum Biotechnologies, Inc.
    • 11.2.2. Arrowhead Pharmaceuticals, Inc.
    • 11.2.3. AstraZeneca PLC
    • 11.2.4. Baxter International Inc.
    • 11.2.5. Biogen Inc.
    • 11.2.6. CSL Behring LLC
    • 11.2.7. GlaxoSmithKline plc
    • 11.2.8. Grifols S.A.
    • 11.2.9. Kamada Ltd.
    • 11.2.10. LFB Biopharmaceuticals
    • 11.2.11. Pfizer Inc.
    • 11.2.12. Prometic Life Sciences Inc.
    • 11.2.13. Shire plc
    • 11.2.14. Takeda Pharmaceutical Company Limited
    • 11.2.15. Vertex Pharmaceuticals Incorporated
    • 11.2.16. Others

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us